S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

Galapagos (GLPG) Competitors

$29.22
-0.27 (-0.92%)
(As of 04/17/2024 ET)

GLPG vs. JANX, VERA, SDGR, PTCT, MRVI, RNA, AMPH, SNDX, DYN, and GPCR

Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Janux Therapeutics (JANX), Vera Therapeutics (VERA), Schrödinger (SDGR), PTC Therapeutics (PTCT), Maravai LifeSciences (MRVI), Avidity Biosciences (RNA), Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), Dyne Therapeutics (DYN), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical preparations" industry.

Galapagos vs.

Galapagos (NASDAQ:GLPG) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.

Galapagos presently has a consensus price target of $34.50, suggesting a potential upside of 18.07%. Janux Therapeutics has a consensus price target of $61.33, suggesting a potential upside of 27.88%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Galapagos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galapagos
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Janux Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Galapagos has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$259.40M7.42$229.12M-$2.29-12.76
Janux Therapeutics$8.08M306.64-$58.29M-$1.34-35.79

Galapagos has a net margin of -26.25% compared to Janux Therapeutics' net margin of -721.18%. Galapagos' return on equity of -2.60% beat Janux Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Galapagos-26.25% -2.60% -1.46%
Janux Therapeutics -721.18%-17.88%-15.95%

Galapagos has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 4.18, suggesting that its share price is 318% more volatile than the S&P 500.

Galapagos received 446 more outperform votes than Janux Therapeutics when rated by MarketBeat users. Likewise, 64.63% of users gave Galapagos an outperform vote while only 58.82% of users gave Janux Therapeutics an outperform vote.

CompanyUnderperformOutperform
GalapagosOutperform Votes
466
64.63%
Underperform Votes
255
35.37%
Janux TherapeuticsOutperform Votes
20
58.82%
Underperform Votes
14
41.18%

32.5% of Galapagos shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Comparatively, 35.4% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Janux Therapeutics had 16 more articles in the media than Galapagos. MarketBeat recorded 18 mentions for Janux Therapeutics and 2 mentions for Galapagos. Janux Therapeutics' average media sentiment score of 0.54 beat Galapagos' score of -0.80 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Galapagos
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative
Janux Therapeutics
7 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Janux Therapeutics beats Galapagos on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLPG vs. The Competition

MetricGalapagosPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.93B$6.59B$4.74B$7.41B
Dividend YieldN/A3.12%5.40%3.96%
P/E Ratio-12.7610.93220.8616.25
Price / Sales7.42280.552,428.3187.67
Price / Cash45.7729.6947.4735.32
Price / Book0.645.374.604.21
Net Income$229.12M$147.85M$101.28M$211.53M
7 Day Performance-6.11%-6.28%-4.64%-4.35%
1 Month Performance-13.98%-6.34%-4.34%-3.37%
1 Year Performance-23.31%-4.38%10.56%4.59%

Galapagos Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JANX
Janux Therapeutics
2.9179 of 5 stars
$40.03
+3.6%
$59.60
+48.9%
+245.3%$2.07B$8.08M-29.8764Analyst Report
News Coverage
VERA
Vera Therapeutics
0.6999 of 5 stars
$37.91
-1.9%
$32.29
-14.8%
+578.9%$2.06BN/A-16.5551
SDGR
Schrödinger
3.5491 of 5 stars
$28.50
+4.4%
$43.50
+52.6%
-9.9%$2.06B$216.67M45.24867Positive News
PTCT
PTC Therapeutics
3.0512 of 5 stars
$27.60
+2.7%
$33.53
+21.5%
-48.7%$2.11B$937.82M-3.30988
MRVI
Maravai LifeSciences
4.2059 of 5 stars
$8.51
+8.1%
$11.13
+30.7%
-42.3%$2.14B$288.95M-9.46650
RNA
Avidity Biosciences
1.0107 of 5 stars
$25.86
+4.4%
$36.33
+40.5%
+59.6%$1.98B$9.56M-8.92253
AMPH
Amphastar Pharmaceuticals
4.7181 of 5 stars
$40.90
-0.4%
$66.00
+61.4%
-3.0%$1.97B$644.40M15.851,761
SNDX
Syndax Pharmaceuticals
2.94 of 5 stars
$23.00
+0.8%
$34.42
+49.6%
+6.4%$1.95B$139.71M-7.77184
DYN
Dyne Therapeutics
3.3124 of 5 stars
$27.23
+1.2%
$37.43
+37.5%
+170.7%$2.23BN/A-6.91141Short Interest ↑
GPCR
Structure Therapeutics
1.6125 of 5 stars
$41.48
-6.6%
$89.17
+115.0%
+55.8%$1.93BN/A-49.9893Short Interest ↑

Related Companies and Tools

This page (NASDAQ:GLPG) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners